21Shares Files Amended S-1 for Spot Injective ETF on Nasdaq
21Shares filed an amended S-1 with the SEC to list a spot Injective ETF (TINJ) on Nasdaq, tracking the INJ token's price. The ETF, sponsored by 21Shares, will hold INJ through Coinbase and BitGo, with FTSE setting the benchmark. Approval from the SEC and Nasdaq is still required.
How this was made

The 30-second read
Why it matters
The amendment adds detail but does not guarantee approval; traders should monitor SEC feedback.
Market read
First filing for a spot INJ ETF could shape future crypto ETF approvals and affect INJ token price.
What to watch
Potential tax and regulatory risks from staking INJ within the trust could deter investors.
Background
21Shares is expanding its crypto ETF lineup; the Injective Network token (INJ) has seen recent institutional use.
Market effects
Adds another alt‑coin ETF candidate, increasing competition among crypto asset managers.
May influence U.S. crypto market sentiment and institutional inflows.
Highlights growing regulatory interest in spot crypto ETFs worldwide.
Counterpoint
SEC may reject the filing, limiting upside and keeping INJ illiquid for retail investors.
Key entities
- Asset Manager21Shares
Issuer of the proposed spot INJ ETF.
- Blockchain ProjectInjective Network
Native token INJ targeted by the ETF.



